Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice

• Main Authors: James D. Chalmers, Abigail Tebboth, Alicia Gayle, Andrew Ternouth, Nick Ramscar
• Format: Article
• Language: English
• Published: Nature Publishing Group 2017-06-01
• Series: npj Primary Care Respiratory Medicine
• Online Access: https://doi.org/10.1038/s41533-017-0040-z

Early-stage chronic lung disease: overuse of inhaled steroids in the UK Inhaled steroids are often prescribed to early-stage chronic lung disease patients in the UK despite guidelines to the contrary. Patients newly diagnosed with early-stage chronic obstructive pulmonary disease (COPD) should not be prescribed inhaled corticosteroids (ICS), because they carry an increased risk of side effects such as pneumonia and osteoporosis. ICS should be reserved for patients with severe COPD and frequent exacerbations. James Chalmers at the Scottish Centre for Respiratory Research, Dundee, and co-workers examined prescribed medication data from the UK spanning 10 years, to determine key predictors of ICS prescription during early-stage COPD. Of 29,815 patients identified, an average of 63% were prescribed ICS upon diagnosis, regardless of disease severity. Younger patients were more likely to receive ICS, possibly due to co-morbidity with chronic asthma, and particular UK regions and medical practices prescribed ICS more readily than others.